source
- FDA grants accelerated approval to Bristol Myers' Zenbexus, first CELMoD for multiple myelomaThe FDA issued an accelerated approval on Thursday for Zenbexus, a multiple myeloma therapy that Bristol Myers Squibb inherited from its Celgene acquisition. Zenbexus belongs to a new class of pro…
- New state and federal funding fuels biotech hub growth in Pennsylvania, Kansas City and beyondGovernment programs in Pennsylvania, New York, Kansas City and Central Virginia are pouring new funding into regional biotech hubs as pharma manufacturing investment surges. Matt Gardner, sector p…